or Try an Advanced Search...

    Technical Analysis for RZLT - Rezolute, Inc.

    Grade Last Price % Change Price Change
    C 4.91 -2.00% -0.10
    RZLT closed up 1.21 percent on Wednesday, November 20, 2024, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical RZLT trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction -2.00%
    Lower Bollinger Band Walk Weakness -2.00%
    Lower Bollinger Band Touch Weakness -2.00%
    Oversold Stochastic Weakness -2.00%
    Below Lower BB Weakness -0.81%
    Lower Bollinger Band Touch Weakness -0.81%
    Oversold Stochastic Weakness -0.81%
    Fell Below 50 DMA Bearish 0.82%
    Expansion Pivot Sell Setup Bearish Swing Setup 0.82%
    Stochastic Reached Oversold Weakness 0.82%
    Older End-of-Day Signals for RZLT ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 minute ago
    Down 2 % about 3 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    Lower Bollinger Band Support about 4 hours ago
    Down 1% about 4 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RZLT Chart by TradingView
    Basic chart:

    Profile

    Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Metabolic Disease Insulin Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein

    Is RZLT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
    Nov 8 Rezolute GAAP EPS of -$0.22
    Nov 7 Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
    Oct 17 With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing
    Sep 19 Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
    Sep 9 Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy
    Sep 9 FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
    Sep 3 Pleasing Signs As A Number Of Insiders Buy Rezolute Stock
    Aug 27 Rezolute to Participate in Upcoming Investor Conferences
    Aug 5 Rezolute gets FDA okay for Phase 3 ersodetug registrational study
    See more RZLT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.1856
    52 Week Low 0.72
    Average Volume 398,589
    200-Day Moving Average 3.82
    50-Day Moving Average 5.14
    20-Day Moving Average 5.51
    10-Day Moving Average 5.44
    Average True Range 0.38
    RSI (14) 42.53
    ADX 22.88
    +DI 15.96
    -DI 22.41
    Chandelier Exit (Long, 3 ATRs) 5.04
    Chandelier Exit (Short, 3 ATRs) 5.81
    Upper Bollinger Bands 6.08
    Lower Bollinger Band 4.94
    Percent B (%b) 0.06
    BandWidth 20.65
    MACD Line 0.01
    MACD Signal Line 0.12
    MACD Histogram -0.1102
    Fundamentals Value
    Market Cap 198.52 Million
    Num Shares 39.6 Million
    EPS -1.10
    Price-to-Earnings (P/E) Ratio -4.55
    Price-to-Sales 0.00
    Price-to-Book 0.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.43
    Resistance 3 (R3) 5.43 5.28 5.36
    Resistance 2 (R2) 5.28 5.17 5.28 5.34
    Resistance 1 (R1) 5.15 5.11 5.21 5.15 5.31
    Pivot Point 5.00 5.00 5.03 5.00 5.00
    Support 1 (S1) 4.86 4.89 4.93 4.87 4.71
    Support 2 (S2) 4.72 4.83 4.72 4.68
    Support 3 (S3) 4.58 4.72 4.66
    Support 4 (S4) 4.59